Allergy Therapeutics plc
AGYTF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $42 | $34 | $22 | $34 |
| % Growth | 22.1% | 57.3% | -35.6% | – |
| Cost of Goods Sold | $28 | $13 | $12 | $13 |
| Gross Profit | $14 | $21 | $9 | $21 |
| % Margin | 32.8% | 61.3% | 42.6% | 61.1% |
| R&D Expenses | $11 | $8 | $12 | $11 |
| G&A Expenses | $9 | $10 | $12 | $11 |
| SG&A Expenses | $19 | $20 | $21 | $21 |
| Sales & Mktg Exp. | $10 | $9 | $9 | $10 |
| Other Operating Expenses | $16 | $2 | $0 | -$0 |
| Operating Expenses | $46 | $29 | $33 | $32 |
| Operating Income | -$20 | -$9 | -$23 | -$12 |
| % Margin | -47.1% | -25.3% | -108.1% | -35.4% |
| Other Income/Exp. Net | -$8 | -$3 | -$1 | -$3 |
| Pre-Tax Income | -$28 | -$11 | -$24 | -$15 |
| Tax Expense | $1 | $0 | $0 | $1 |
| Net Income | -$40 | -$11 | -$25 | -$16 |
| % Margin | -96% | -32.6% | -113.6% | -46.6% |
| EPS | -0.008 | -0.002 | -0.005 | -0.006 |
| % Growth | -265.2% | 55.8% | 10.3% | – |
| EPS Diluted | -0.008 | -0.002 | -0.005 | -0.006 |
| Weighted Avg Shares Out | 4,766 | 4,768 | 4,767 | 2,720 |
| Weighted Avg Shares Out Dil | 4,766 | 4,766 | 4,766 | 2,720 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | -$0 | $0 |
| Interest Expense | $6 | $3 | $0 | $6 |
| Depreciation & Amortization | $4 | $2 | $0 | $2 |
| EBITDA | -$36 | -$4 | -$23 | -$9 |
| % Margin | -87.3% | -12.2% | -105.5% | -27.9% |